Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 15;13(1):16-24.
doi: 10.5009/gnl18071.

Recurrent Clostridium difficile Infection: Risk Factors, Treatment, and Prevention

Jung Hoon Song  1 , You Sun Kim  2
Affiliations
Review

Recurrent Clostridium difficile Infection: Risk Factors, Treatment, and Prevention

Jung Hoon Song et al. Gut Liver. .

Abstract

The most common cause of antibiotic-associated diarrhea is Clostridium difficile infection (CDI). Recurrent C. difficile infection (rCDI) often occurs after successful treatment of CDI. Due to the increased incidence and the difficulty in treating rCDI, it is becoming an important clinical issue. Identifying risk factors is helpful for early detection, treatment, and prevention of rCDI. Advanced age, use of antibiotics, gastric acid suppression, and infection with a hypervirulent strain are currently regarded as the major risk factors for rCDI. Several treatment modalities, including vancomycin, fidaxomicin, and fecal microbiota transplant (FMT), are suggested for rCDI treatment. However, there is currently no definitive treatment method with sufficient evidence for rCDI. Recent studies have focused on FMT and have shown positive results for rCDI. Prevention of rCDI by measures such as hand washing and isolation of patients is very important. However, these preventive measures are often overlooked in clinical practice. Here, we review the risk factors, treatment, and prevention of rCDI.

Keywords: Clostridium difficile; Prevention; Recurrence; Risk factors; Therapeutics.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

References

    1. Bartlett JG, Moon N, Chang TW, Taylor N, Onderdonk AB. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology. 1978;75:778–782. - PubMed
    1. Burke KE, Lamont JT. Clostridium difficile infection: a worldwide disease. Gut Liver. 2014;8:1–6. doi: 10.5009/gnl.2014.8.1.1. - DOI - PMC - PubMed
    1. Kim YS, Han DS, Kim YH, et al. Incidence and clinical features of Clostridium difficile infection in Korea: a nationwide study. Epidemiol Infect. 2013;141:189–194. doi: 10.1017/S0950268812000581. - DOI - PMC - PubMed
    1. Lee JH, Lee SY, Kim YS, et al. The incidence and clinical features of Clostridium difficile infection; single center study. Korean J Gastroenterol. 2010;55:175–182. doi: 10.4166/kjg.2010.55.3.175. - DOI - PubMed
    1. Pépin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171:466–472. doi: 10.1503/cmaj.1041104. - DOI - PMC - PubMed

MeSH terms

Substances